Drug Discovery & Development

Drug Discovery & Development
Share

Lion Biotechnologies, Inc.’s LN-144 achieved a 29 percent objective response rate in a study of patients with advanced metastatic melanoma. The biotechnology company presented the new data from an ongoing Phase II melanoma study evaluating its lead immunotherapy candidate LN-144 at the 2017 ASCO Annual Meeting in Chicago. LN-144, Lion’s...

The U.S. Food and Drug Administration (FDA) approved Rituxan Hycela for subcutaneous injection. According to the company, this new treatment includes the same monoclonal antibody as intravenous rituximab (Rituxan) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. The new formulation can be...

Drug Discovery & Development

 •  March 9, 2015

Astellas announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). These are life ...